Optinose Inc (OPTN) Return on Investment ROI from the first quarter of 2025 to first quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket
 


Optinose Inc   (NASDAQ: OPTN)


Optinose Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Optinose Inc's ROI in the first quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Optinose Inc 's return on investment (ROI) in its first quarter of 2025

Definition and Formula of Return on Investment



Return On Investment (Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions -60 -34 -31 84 33
Return On Investment (TTM) - - - 350.74 % 61.5 %
OPTN's Overall Ranking # # # # #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -30 -22 -31 -41 -31




Return On Investment OPTN's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Optinose Inc's I. Quarter Investments $ -60 Millions OPTN's Balance sheet
Optinose Inc's I. Quarter Income $ -22 Millions Quarterly OPTN's Income Statement
OPTN's Income by Division See OPTN's Income by Division


OPTN Annual Return On Investment (Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
Total Investments in Millions -34 -86 -56 107 137
Y / Y Investment Growth - - - -21.81 % 0.1 %
Net Income in Millions -22 -35 -75 -82 -100
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - -77.03 % -73.03 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
OPTN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for OPTN's Competitors
Subscribers only: Roi for Optinose Inc's Suppliers
Subscribers only: Return On Investment for OPTN's Customers

Other Ratios
OPTN's Roa OPTN's Inventory Turnover Ratio OPTN's Growth Rates OPTN's Dividend Statistics
OPTN's Profitability Ratios OPTN's Asset Turnover Ratio OPTN's Dividend Growth
OPTN's Roe OPTN's Valuation Ratios OPTN's Financial Strength Ratios OPTN's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector ROI
Capforce Inc   322.66 %
Pavmed Inc   314.73 %
Interpace Biosciences Inc   213.95 %
Cytomx Therapeutics Inc   139.64 %
Camp4 Therapeutics Corporation  136.24 %
Alumis inc   113.83 %
Stablecoin Development Corporation  110.75 %
Earth Science Tech Inc   100.58 %
Oak Woods Acquisition Corp  93.88 %
Avalo Therapeutics Inc   88.86 %
Tao Synergies Inc   78.95 %
Synlogic Inc   73.65 %
Novavax inc   71.31 %
Medinotec Inc   60.77 %
Exelixis Inc   59.41 %
Gridai Technologies Corp  58.38 %


Date modified: 2026-09-26T07:37:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.